// App-Quantinova.ai

CT141 : Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer

Researchers

Presenter

  • James Spicer

Principal Investigators

  • Ana Montes

  • Udai Banerji

  • Rebecca Kristeleit

  • Gareth J. Veal

  • Christopher Corrigan

  • Stephen Till

  • George Nintos

  • Timothy Brier

  • Ionut G. Funingana

  • Joo Ern Ang

  • Kam Zaki

  • Annie Griffin

  • Claire Barton

  • Paul Jones

  • Sarah Mellor

  • Susan Brook

  • Katie Stoddart

  • Christopher Selkirk

  • Simon Carroll

  • Heike Lentfer

  • Natalie Woodman

  • Amy Pope

  • Giulia Pellizzari

  • Mano Nakamura

  • Kristina M. Ilieva

  • Atousa Khiabany

  • Chara Stavraka

  • Hannah Gould

  • Jitesh Chauhan

  • Heather Bax

  • Sarah Pinder

  • Debra Josephs

  • Sophia Karagiannis

Medical Centers

  • Kings College London, London, United Kingdom

  • University of Cambridge, Cambridge, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Kings College London, London, United Kingdom

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • Barton Oncology Ltd, London, United Kingdom

  • Cancer Research UK, Southampton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Immunoglobulin E

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved